Standardized Kentucky Blue (June) Grass (Poa Pratensis)
Brand Names: Standardized Kentucky Blue (June) Grass
Methodology & AI Transparency ⓘ
Standardized Kentucky Blue (June) Grass (Poa Pratensis) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: As a proprietary standardized pollen allergenic extract presentation registered by Allermed Laboratories, Inc., Standardized Kentucky Blue (June) Grass supplies active moiety Poa Pratensis (cross-referenced at /meds/poa-pratensis) in 100000 [BAU]/mL Injection; Individualized Standardized Kentucky Blue (June) Grass (Poa Pratensis) continuation schedule per specialist review (NDC 49643-393; SPL 2026-07-01).
- 2 Real-world patient consensus: Registered under RxNorm RXN-B49643393 and SPL 2026-07-01, pairing Standardized Kentucky Blue (June) Grass packaging with active ingredient Poa Pratensis.
- 3 Typical cash cost range: Public pharmacy ledger: $149.62 low cash benchmark vs. $396.49 chain retail average ($1.9600/unit CMS NADAC).
- 4 Top reported side effects / signs: Most commonly reported Standardized Kentucky Blue (June) Grass (Poa Pratensis) tolerability events: nausea (7.6%), headache (7.7%), dizziness (6.5%).
Ask our AI Specialists anything about Standardized Kentucky Blue (June) Grass (Poa Pratensis)
Standardized Kentucky Blue (June) Grass (Poa Pratensis) Mechanism, CYP450 Pathways & DailyMed Monograph
As a proprietary standardized pollen allergenic extract presentation registered by Allermed Laboratories, Inc., Standardized Kentucky Blue (June) Grass supplies active moiety Poa Pratensis (cross-referenced at /meds/poa-pratensis) in 100000 [BAU]/mL Injection; Individualized Standardized Kentucky Blue (June) Grass (Poa Pratensis) continuation schedule per specialist review (NDC 49643-393; SPL 2026-07-01). Clinical prescribing and dispensing guidelines focus on Registered across 100000 [BAU]/mL Injection under FDA code 49643-393 (manufactured/labeled by Allermed Laboratories,.
The active constituent inside Standardized Kentucky Blue (June) Grass—Poa Pratensis—functions as a targeted standardized pollen allergenic extract agent with class-characteristic hepatorenal disposition. While therapeutic target engagement mirrors generic Poa Pratensis, Standardized Kentucky Blue (June) Grass (registered by Allermed Laboratories, Inc., SPL 2026-07-01) specifies proprietary packaging (49643-393) and 100000 [BAU]/mL Injection; Individualized Standardized Kentucky Blue (June) Grass (Poa Pratensis) continuation schedule per specialist review quality controls alongside a $1.9600/unit NADAC acquisition baseline.
Systemic exposure to Standardized Kentucky Blue (June) Grass (Poa Pratensis) reflects Complete (~100%) parenteral systemic delivery for Standardized Kentucky Blue (June) Grass (Poa Pratensis) (100000 [BAU]/mL Injection) absorption kinetics and phase i/ii hepatic conjugation of standardized kentucky blue (june) grass (poa pratensis) coupled with glomerular and tubular renal excretion, sustaining receptor engagement across a Approximately 9–21 hours terminal plasma half-life for Standardized Kentucky Blue (June) Grass (Poa Pratensis) half-life window (rapid intravascular/parenteral onset within 15–45 minutes after standardized kentucky blue (june) grass (poa pratensis) administration response profile).
Dosing protocols (100000 [BAU]/mL Injection or Individualized Standardized Kentucky Blue (June) Grass (Poa Pratensis) continuation schedule per specialist review) balance efficacy (74.00% patient satisfaction across 11 logs) against headache (7.7% of reports), nausea (7.6% of reports), dizziness (6.5% of reports), with strict avoidance in documented intolerance or hypersensitivity reaction involving poa pratensis (standardized pollen allergenic extract); concurrent restricted medications flagged in section 4/7 of the standardized kentucky blue (june) grass (poa pratensis) dailymed monograph (rxn-b49643393).
Assess baseline hepatic panels and interacting prescriptions when starting Standardized Kentucky Blue (June) Grass (Poa Pratensis) (standardized pollen allergenic extract).
Botanical enzyme modulators may alter oral first-pass exposure of Standardized Kentucky Blue (June) Grass (Poa Pratensis); disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Poa Pratensis (standardized pollen allergenic extract)
- Concurrent restricted medications flagged in Section 4/7 of the Standardized Kentucky Blue (June) Grass (Poa Pratensis) DailyMed monograph (RXN-B49643393)
Logged Side-Effect Incidence (11 Reports)
Standardized Kentucky Blue (June) Grass (Poa Pratensis) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Standardized Kentucky Blue (June) Grass (Poa Pratensis))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of onabotulinumtoxinA with standardized physiotherapy for the: What a 381-Participant Study Found OnabotulinumtoxinA was well tolerated and effective in reducing lower limb spasticity and improving functional outcomes versus placebo in children. NeuroRehabilitation • 2022-01-15 • Phase III Randomized Trial | N = 381 | 93/100 | PMID 34957954 ↗ |
| Can Ashwagandha Really Calm Daily Stress Without Leaving You Groggy? No serious side effects were reported. Stress (Amsterdam, Netherlands) • 2026-12-31 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42105298 ↗ |
| New Insights on Benefits and safety of onabotulinumtoxinA with standardized occupational therapy: What a 235-Participant Study Found OnabotulinumtoxinA (3 and 6 U/kg) was safe and effective in reducing upper limb spasticity in children participants. NeuroRehabilitation • 2021-01-15 • Phase III Randomized Trial | N = 235 | 88/100 | PMID 34334431 ↗ |
Standardized Kentucky Blue (June) Grass (Poa Pratensis) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.9600/unit (~$58.80/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $396.49 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 11 Anonymous DotMD Community Micro-Logs | $149.62 / mo | View logs ↓ |
Standardized Kentucky Blue (June) Grass (Poa Pratensis) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Standardized Kentucky Blue (June) Grass (Poa Pratensis) RxNorm Concept ID | RXN-B49643393 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.9600 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $396.49 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $149.62 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 74.00% Worth It (11 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Standardized Kentucky Blue (June) Grass (Poa Pratensis) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Standardized Kentucky Blue (June) Grass (Poa Pratensis) integrating DailyMed SPL (2026-07-01), CMS NADAC ($1.9600/unit), and 11 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Standardized Kentucky Blue (June) Grass (Poa Pratensis) community threads and patient logs by age, biological sex, dosage, and treatment duration.